Categories: Financial Results

Cipla announces Q2 FY19 results

Mumbai, November 28, 2018: Cipla Limited (BSE: 500087, NSE: CIPLA) today announced its unaudited consolidated financial results for quarter ended September 30, 2018.

Key highlights of the quarter

  • R&D investments at ~INR 316cr / ~8% of sales
  • Continued growth momentum: Growth in private market [non-tender] segments
    continues strong across India, the US, South Africa and Emerging Markets
  • US business sales trajectory improves with 12% YoY growth driven by contribution from
    new launches. 7 new approvals in the quarter with multiple limited competition assets
    getting launched
  • Quality Focus: Inspection at Goa plant concludes with minor procedural observations

Read more

Corporate Comm India(CCI Newswire)

The Pharma Times News Bureau

Recent Posts

Lung Cancer Awareness Month

By Dr. C N Patil, HOD and Lead Consultant - Medical Oncology & Haemato-Oncology, Aster…

13 hours ago

Unmasking COPD: The Silent Respiratory Threat of Smoking

By  Dr. Pavan Yadav, Lead Consultant - Interventional Pulmonology & Lung Transplantation, Aster RV Hospital …

13 hours ago

Khazi India Foundation to Host Expert Cardiac Consultations in Adoni

Kurnool, November 20, 2024: Adoni, Andhra Pradesh, – The Khazi India Foundation is pleased to…

1 day ago

Aakash Healthcare Celebrates Children’s Day with Kids from Choti Si Khushi

New Delhi, November 20, 2024: Aakash Healthcare marked this year’s Children’s Day with a joyful…

1 day ago

Annual eye screening crucial for diabetic patients to protect eyesight: Dr Agarwals Eye Hospital

Dr Agarwals Eye Hospital, Bengaluru, is providing free consultations for diabetic patients aged 50 and…

4 days ago

7 Signs You Are Suffering From Protein Deficiency

By Ms. Archana S, Senior Nutritionist, Aster Whitefield Hospital, Bengaluru As an essential nutrient, protein…

4 days ago